Cetera Investment Advisers increased its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 497.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,512 shares of the company’s stock after buying an additional 14,582 shares during the quarter. Cetera Investment Advisers owned about 0.06% of Inspire Medical Systems worth $2,344,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Van ECK Associates Corp raised its position in Inspire Medical Systems by 7.5% in the second quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock valued at $138,000 after purchasing an additional 72 shares during the period. Amalgamated Bank boosted its stake in Inspire Medical Systems by 4.1% during the second quarter. Amalgamated Bank now owns 2,005 shares of the company’s stock worth $268,000 after buying an additional 79 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Inspire Medical Systems by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,193 shares of the company’s stock valued at $2,836,000 after acquiring an additional 92 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Inspire Medical Systems by 1.2% in the 1st quarter. Bessemer Group Inc. now owns 8,475 shares of the company’s stock worth $1,820,000 after acquiring an additional 100 shares during the last quarter. Finally, Gilliland Jeter Wealth Management LLC boosted its position in shares of Inspire Medical Systems by 0.8% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 15,508 shares of the company’s stock worth $2,075,000 after purchasing an additional 125 shares during the period. 94.91% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Inspire Medical Systems
In related news, Director Shawn Mccormick sold 800 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the sale, the director now directly owns 23,140 shares of the company’s stock, valued at $5,090,800. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Randy Ban sold 4,861 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $188.55, for a total value of $916,541.55. Following the completion of the sale, the insider now directly owns 3,056 shares of the company’s stock, valued at approximately $576,208.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares in the company, valued at approximately $5,090,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,692 shares of company stock worth $1,099,207. Corporate insiders own 4.10% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on Inspire Medical Systems
Inspire Medical Systems Stock Up 2.6 %
Shares of INSP opened at $210.83 on Friday. The company has a market capitalization of $6.29 billion, a price-to-earnings ratio of 1,171.28 and a beta of 1.34. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $257.40. The stock has a 50 day moving average price of $197.04 and a 200 day moving average price of $183.21.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. Inspire Medical Systems had a net margin of 0.85% and a return on equity of 1.03%. The firm had revenue of $195.89 million for the quarter, compared to the consensus estimate of $189.08 million. During the same period last year, the firm posted ($0.41) EPS. The company’s revenue was up 29.6% on a year-over-year basis. On average, equities analysts anticipate that Inspire Medical Systems, Inc. will post 0.75 EPS for the current fiscal year.
Inspire Medical Systems Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Featured Articles
- Five stocks we like better than Inspire Medical Systems
- Quiet Period Expirations Explained
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What is a Dividend King?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Stock Dividend Cuts Happen Are You Ready?
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP – Free Report).
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.